Karl Brendel

1.3k total citations
19 papers, 1.1k citations indexed

About

Karl Brendel is a scholar working on Statistics and Probability, Molecular Biology and Oncology. According to data from OpenAlex, Karl Brendel has authored 19 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Statistics and Probability, 6 papers in Molecular Biology and 5 papers in Oncology. Recurrent topics in Karl Brendel's work include Statistical Methods in Clinical Trials (8 papers), Statistical Methods and Bayesian Inference (4 papers) and Lung Cancer Research Studies (3 papers). Karl Brendel is often cited by papers focused on Statistical Methods in Clinical Trials (8 papers), Statistical Methods and Bayesian Inference (4 papers) and Lung Cancer Research Studies (3 papers). Karl Brendel collaborates with scholars based in France, Spain and United States. Karl Brendel's co-authors include Emmanuelle Comets, France Mentré, Céline M. Laffont, Christian Laveille, Annabelle Lemenuel‐Diot, Brigitte Tranchand, Pascal Girard, Marylore Chenel, Odile Launay and Laurence Gérard and has published in prestigious journals such as Annals of Oncology, European Journal of Cancer and Pharmaceutical Research.

In The Last Decade

Karl Brendel

18 papers receiving 1.1k citations

Peers

Karl Brendel

PHARM

PPCH

ONCOL

MO Karlsson Sweden

DR Mould United States

Stefanie Hennig Australia

Jakob Ribbing Sweden

Christian Laveille France

Helen Kastrissios United States

Janet R. Wade United States

Nidal Al‐Huniti United States

Dong‐Seok Yim South Korea

Elizabeth Ludwig United States

MO Karlsson Sweden

Karl Brendel

242 ×0.7

PHARM

192 ×0.7

PPCH

240 ×1.4

ONCOL

206 ×1.2

148 ×1.0

Citations per year, relative to Karl Brendel Karl Brendel (= 1×) peers MO Karlsson

Countries citing papers authored by Karl Brendel

Since Specialization

Citations

This map shows the geographic impact of Karl Brendel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karl Brendel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karl Brendel more than expected).

Fields of papers citing papers by Karl Brendel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karl Brendel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karl Brendel. The network helps show where Karl Brendel may publish in the future.

Co-authorship network of co-authors of Karl Brendel

This figure shows the co-authorship network connecting the top 25 collaborators of Karl Brendel. A scholar is included among the top collaborators of Karl Brendel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karl Brendel. Karl Brendel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Brendel, Karl, et al.. (2025). Using Fisher Information Matrix to predict uncertainty in covariate effects and power to detect their relevance in Non-Linear Mixed Effect Models in pharmacometrics. Journal of Pharmacokinetics and Pharmacodynamics. 52(4). 38–38.

Brendel, Karl, Tanios Bekaii‐Saab, Patrick M. Boland, et al.. (2021). Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure–safety analyses in patients with metastatic pancreatic cancer. CPT Pharmacometrics & Systems Pharmacology. 10(12). 1550–1563. 10 indexed citations

Ponce, Santiago, Karl Brendel, David R. Spigel, et al.. (2020). 1793P RESILIENT part 1: Pharmacokinetics of second-line (2L) liposomal irinotecan in patients with small cell lung cancer (SCLC). Annals of Oncology. 31. S1038–S1039. 1 indexed citations

Brendel, Karl, et al.. (2020). TrainX – Named Entity Linking with Active Sampling and Bi-Encoders. 64–69. 1 indexed citations

Macarulla, Teresa, Karl Brendel, Christopher H. Lieu, et al.. (2019). Integrated population pharmacokinetic modelling of liposomal irinotecan in patients with various tumour types, including untreated metastatic pancreatic cancer (mPC). Annals of Oncology. 30. v263–v263. 2 indexed citations

Lavielle, Marc, et al.. (2018). Development and performance of npde for the evaluation of time-to-event models. Pharmaceutical Research. 35(2). 30–30. 4 indexed citations

Rodón, Jordi, Sophie Postel‐Vinay, Antoine Hollebecque, et al.. (2017). First-in-human phase I study of oral S49076, a unique MET/AXL/FGFR inhibitor, in advanced solid tumours. European Journal of Cancer. 81. 142–150. 27 indexed citations

Postel‐Vinay, Sophie, Antoine Hollebecque, Jean‐Charles Soria, et al.. (2015). 125O First-in-human study of oral S 49076, a MET/AXL/FGFR inhibitor, in advanced solid tumors. Annals of Oncology. 26. ix37–ix37. 1 indexed citations

Bouzom, François, et al.. (2015). Model-based approaches for ivabradine development in paediatric population, part I: study preparation assessment. Journal of Pharmacokinetics and Pharmacodynamics. 43(1). 13–27. 12 indexed citations

10.

Mentré, France, et al.. (2012). Optimal Sampling Times for a Drug and its Metabolite using SIMCYP® Simulations as Prior Information. Clinical Pharmacokinetics. 52(1). 43–57. 24 indexed citations

11.

Comets, Emmanuelle & Karl Brendel. (2010). Model evaluation in nonlinear mixed effect models, with applications to pharmacokinetics. French digital mathematics library (Numdam). 151(1). 106–128. 29 indexed citations

12.

Brendel, Karl, Emmanuelle Comets, Céline M. Laffont, & France Mentré. (2009). Evaluation of different tests based on observations for external model evaluation of population analyses. Journal of Pharmacokinetics and Pharmacodynamics. 37(1). 49–65. 66 indexed citations

13.

Comets, Emmanuelle, Karl Brendel, & France Mentré. (2008). Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: The npde add-on package for R. Computer Methods and Programs in Biomedicine. 90(2). 154–166. 380 indexed citations

14.

Brendel, Karl, Emmanuelle Comets, Céline M. Laffont, et al.. (2007). Overview of model‐building strategies in population PK/PD analyses: 2002–2004 literature survey. British Journal of Clinical Pharmacology. 64(5). 603–612. 70 indexed citations

15.

Brendel, Karl, Emmanuelle Comets, Annabelle Lemenuel‐Diot, et al.. (2007). Are Population Pharmacokinetic and/or Pharmacodynamic Models Adequately Evaluated?. Clinical Pharmacokinetics. 46(3). 221–234. 145 indexed citations

16.

Brendel, Karl, Emmanuelle Comets, Céline M. Laffont, Christian Laveille, & France Mentré. (2006). Metrics for External Model Evaluation with an Application to the Population Pharmacokinetics of Gliclazide. Pharmaceutical Research. 23(9). 2036–2049. 263 indexed citations

17.

Brendel, Karl, et al.. (2005). Population pharmacokinetic analysis of indinavir in HIV‐infected patient treated with a stable antiretroviral therapy. Fundamental and Clinical Pharmacology. 19(3). 373–383. 14 indexed citations

18.

Verstuyft, Céline, Fabienne Marcellin, Laurence Morand‐Joubert, et al.. (2005). Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy. AIDS. 19(18). 2127–2131. 37 indexed citations

19.

Katz, Joanne, et al.. (1997). Efficiency of EPI cluster sampling for assessing diarrhoea and dysentery prevalence.. PubMed. 75(5). 417–26. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact